Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

238 results about "Cells embryo" patented technology

Embryonic stem cells (ES cells or ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells.

Inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells

The invention discloses an inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells. The method comprises the steps of: cultivating the human embryonic stem cells on a mouse embryonic fibroblast feed layer; sorting human embryonic stem cell clone groups in good state; grafting the groups on a human corneal stromal fibroblast layer processed by mitomycin C and cultivating for 7 days, wherein the human embryonic stem cells are differentiated to rosettes; separating and transferring the rosettes from the human corneal stromal fibroblast layer to a culture bottle; cultivating continuously for 7 days by using a neural crest stem cell culture medium; sorting the neural crest stem cells by a flow cytometry; adding the neural crest stem cells into the culture bottle; placing in a 5% CO2 incubator for incubating and cultivating at 37 DEG C by using a human corneal endothelial cell culture medium; changing the liquid every other day; and cultivating for about 10 days to obtain the corneal endothelial cells. The multiplication capacity of the corneal endothelial cells are similar to that of human corneal endothelial cells and the corneal endothelial cells can be transferred to 1-2 generations in vitro maximally. The corneal endothelial cells can be used as seed cells for cornea construction and transplant in tissue engineering.
Owner:SHANDONG UNIV

Micropropagation method of fraxinus rhynchophylla

The invention discloses a micropropagation method of fraxinus rhynchophylla and relates to the micropropagation method. The problems of long reproductive cycle, low reproduction efficiency and poor offspring genetic stability in nursery stock propagation of fraxinus rhynchophylla are solved. The method comprises the following steps of: 1, sterilizing fraxinus rhynchophylla seeds, and culturing single cotyledons of zygotic embryos to obtain cotyledonal cell embryos; 2, performing maturation cultivation on the cotyledonal cell embryos; 3, performing sprouting cultivation on the cotyledonal cellembryos subjected to maturation cultivation to obtain regenerated plants; and 4, transplanting the regenerated plants into a culture medium to culture until new leaves are completely unfolded, and removing a covered plastic thin film. The micropropagation method has the advantages of short nursery stock reproductive cycle, high reproductive rate (culturing for 60 to 70 days) and high reproductionefficiency (each explant can generate 15 to 20 somatic embryos); the germination rate of the somatic embryos is up to 87 to 89.55 percent; the transplanting survival rate of the regenerated plants isup to 75 to 80 percent; and the regeneration plants with the same good characteristics as female parents can be generated in mass.
Owner:NORTHEAST FORESTRY UNIVERSITY +2

Metabolite for improving production, maintenance and proliferation of pluripotent stem cells, composition comprising the same, and method of culturing pluripotent stem cell using the same

InactiveUS20150072416A1Improve efficiencyInhibits induction of senescenceOrganic chemistryCulture processMetaboliteReprogramming
According to the present invention, when nicotinamide is added in a culture process for producing pluripotent stem cells from human differentiated cells, it can increase the efficiency of reprogramming and can significantly reduce the time required for induction of reprogramming. It was verified that nicotinamide inhibits the induction of senescence and oxidative stress in the reprogramming process and increases cell proliferation and mitochondrial activity to effectively improve culture conditions for induction of reprogramming. Particularly, the present invention will contribute to optimizing a process of producing induced pluripotent stem cells from a small amount of patient-specific somatic cells obtained from various sources, and thus it will significantly improve a process of developing clinically applicable personalized stem cell therapy agents and new drugs and will facilitate the practical application of these agents and drugs. In another aspect, according to the present invention, in defined culture conditions in which feeder cells and serum were not used, it was found that nicotinamide can provide a culture medium composition effective for maintaining the undifferentiated state of human embryonic stem cells and human induced pluripotent stem cells, which are typical pluripotent stem cells. The invention can be effectively used for the development of a high-efficiency system for culturing large amounts of human pluripotent stem cells, which is required for the industrialization of human pluripotent stem cells.
Owner:KOREA RES INST OF BIOSCI & BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products